Living with an external feeding tube and another tube in his neck to help him breathe?
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Living with an external feeding tube and another tube in his neck to help him breathe?
That wasn’t going to work for Vic Padilla, a 72-year-old builder of racing motorcycles and custom hot rods. He had too many things left to do, too many racetracks left unconquered.
Lung Cancer Liver Cancer Pancreatic Cancer Esophageal Cancer Stomach Cancer
A key yardstick used to evaluate success in cancer treatment shows that for many cancers, a higher percentage of people diagnosed at the University of Colorado Cancer Center have survived five years or more beyond their diagnoses than for the nation as a whole.
Research Esophageal Cancer Pediatrics Bioengineering
It looks pretty simple: A capsule the size of a jelly bean, attached to a string. And yet, it shows promise as an answer to a vexing question in the fight against esophageal cancer and other diseases of the upper digestive tract: How to spare patients from repeated endoscopies and biopsies.
Patient Care Esophageal Cancer Clinical Trials
Mark Koebrich's heartburn, a lifelong companion through nearly four decades in television, took a turn for the worse after retirement, prompting him to seek medical advice. His general practitioner referred him to UCHealth University of Colorado Hospital, where he met Sachin Wani, MD, the Endowed Chair of the Katy O. and Paul M. Esophageal and Gastric Center of Excellence. Koebrich was diagnosed with Barrett's esophagus with low-grade dysplasia, a precancerous condition, and was enrolled in the SURVENT trial, a groundbreaking study offering cutting-edge treatment options.
Esophageal Cancer Multidisciplinary Clinic
The University of Colorado Cancer Center’s new Benign Esophageal and Gastric Multidisciplinary Clinic has its first medical director.
A project to improve the effectiveness of endoscopic surgery, led by University of Colorado Cancer Center member Steven Edmundowicz, MD, is one of nine research endeavors to be awarded major funding from the Anschutz Acceleration Initiative (AAI).
Research COVID-19 Esophageal Cancer
The COVID-19 pandemic had dramatic effects on all types of cancer screenings, from mammograms to colonoscopies. In the early days of the health crisis in spring 2020, screening numbers dropped dramatically as health care providers shifted their attention to caring for the seriously ill and fears of contracting the virus kept the general public away from hospitals, clinics, and other facilities.
University of Colorado Cancer Center member Sachin Wani, MD, inaugural director of the Katy O. and Paul M. Rady Esophageal and Gastric Center of Excellence, is behind a new clinic for people with benign, complex conditions of the foregut, including complicated reflux cases, refractory esophageal strictures, and motility disorders such as achalasia and gastroparesis.
Patient Care Esophageal Cancer
Nathan Hammond knew things were getting bad when his doctors had to put the feeding tube in.
Research Philanthropy Esophageal Cancer
Funding from the Paul R. O’Hara Seed Grant Fund at the University of Colorado Anschutz Medical Campus will allow CU Cancer Center member Akshay Chauhan, MD, to explore new methods of detecting and treating esophageal cancer.
Research Patient Care Awareness Esophageal Cancer
Less than a year ago, Ken Herfert got a puppy and named her Bailey after the Colorado town where she was born.
This was a big deal for several reasons, including the responsibility of adopting a new family member, but perhaps the biggest was this: About six months after receiving a diagnosis of esophageal cancer in early 2018, Herfert’s oncologist in California told him he had maybe a year to live, maybe less.
On a mission to increase early detection of esophageal cancer, University of Colorado (CU) Cancer Center member Sachin Wani, MD, is leading a study to see if a novel diagnostic platform can help endoscopists better identify the disease in patients with a condition called Barrett’s esophagus.
Research Patient Care Esophageal Cancer Surgical Oncology Clinical Trials
Looking for better ways to treat patients with esophageal cancer, University of Colorado Cancer Center member Martin McCarter, MD, is investigating whether a new treatment sequence will result in better outcomes.
Esophageal cancer is cancer that arises in the esophagus – a hollow, muscular tube that is about a foot long. It helps pass food and liquids from the back of the mouth to the stomach. The esophagus lies just behind the trachea and in front of the spine. Esophageal cancer begins in the cells that line the inside of the esophagus.
Katy Rady lost her brother, Paul, to cancer nearly four years ago. Katy and her husband, also named Paul, turned their grief into a mission to prevent other families from having to go through the same pain. That mission led to the Paul R. O’Hara II Esophagogastric Cancer Symposium.
Patient Care Faculty Esophageal Cancer
When Tom Donahue came to UCHealth University of Colorado Hospital (UCH), University of Colorado Cancer Center’s clinical partner, he thought he had a pre-cancerous condition called Barrett’s Esophagus. But Donahue had a diagnosis of Barrett’s esophagus with high-grade dysplasia (precancerous cells) and an oncologist in Scottsbluff, Nebraska referred to him to UCH because he needed to see a specialist.
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.